Daniel Freeman

Daniel Freeman is an accomplished leader in oncology research and development with extensive experience spanning over two decades. Currently serving as Vice President of Early Development Oncology at AstraZeneca since June 2016, Freeman oversees a top-tier R&D project team focused on various advanced cancer therapies, successfully transitioning six New Molecular Entities to late development from 2021 to 2023. Previous roles include Head of Next Generation Oncology Development at MedImmune, Group Director of Oncology Biomarkers at Bristol-Myers Squibb, and Senior Director of Translational Medicine & Clinical Pharmacology at Daiichi Sankyo, where Freeman led significant biomarker initiatives in clinical development. Freeman began a career in oncology at Amgen as Principal Scientist, where the discovery of a crucial biomarker for colorectal cancer treatment took place. Freeman holds a PhD in Molecular and Medical Pharmacology from UCLA and a BS in Pharmacology from UC Santa Barbara.